NO20062619L - Doseringssystem med kontrollert frigivning for nasale anvendelser - Google Patents
Doseringssystem med kontrollert frigivning for nasale anvendelserInfo
- Publication number
- NO20062619L NO20062619L NO20062619A NO20062619A NO20062619L NO 20062619 L NO20062619 L NO 20062619L NO 20062619 A NO20062619 A NO 20062619A NO 20062619 A NO20062619 A NO 20062619A NO 20062619 L NO20062619 L NO 20062619L
- Authority
- NO
- Norway
- Prior art keywords
- controlled release
- dosing system
- release dosing
- nasal applications
- nasal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
Abstract
Oppfinnelsen vedrører et preparat for nasal administrering for kontrollert fligivning av kjørmshormoner til systemisk sirkulasjon, spesielt til formulering som muliggjør at den aktive ingrediensen absorberes på en vedvarende måte for å tilveiebringe en bedre biotilgjengelighet ved meget lave doser og langvarig virkning.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03025769A EP1530965B1 (en) | 2003-11-11 | 2003-11-11 | Controlled release delivery system of sexual hormones for nasal application |
PCT/EP2004/012122 WO2005044273A1 (en) | 2003-11-11 | 2004-10-27 | Controlled release delivery system for nasal applications |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20062619L true NO20062619L (no) | 2006-06-07 |
NO338665B1 NO338665B1 (no) | 2016-09-26 |
Family
ID=34429314
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20062619A NO338665B1 (no) | 2003-11-11 | 2006-06-07 | Doseringssystem med kontrollert frigivning for nasale anvendelser |
Country Status (23)
Country | Link |
---|---|
US (6) | US20050100564A1 (no) |
EP (1) | EP1530965B1 (no) |
JP (1) | JP4616270B2 (no) |
KR (1) | KR100861443B1 (no) |
AR (1) | AR047722A1 (no) |
AT (1) | ATE319426T1 (no) |
AU (1) | AU2004286781B2 (no) |
BR (1) | BRPI0416370B8 (no) |
CA (1) | CA2541498C (no) |
DE (1) | DE60303854T2 (no) |
DK (1) | DK1530965T3 (no) |
ES (1) | ES2258694T3 (no) |
HR (1) | HRP20060147B1 (no) |
MY (1) | MY131483A (no) |
NO (1) | NO338665B1 (no) |
PL (1) | PL219338B1 (no) |
PT (1) | PT1530965E (no) |
RU (1) | RU2331423C2 (no) |
SA (1) | SA04250363B1 (no) |
SI (1) | SI1530965T1 (no) |
TW (1) | TWI350176B (no) |
WO (1) | WO2005044273A1 (no) |
ZA (1) | ZA200603115B (no) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TR199900645T2 (xx) | 1996-10-01 | 1999-07-21 | Fran�Ois Hubert | Bile�ik a��nma par�as�. |
JP4222944B2 (ja) | 2001-12-04 | 2009-02-12 | マゴット アンテルナショナル エス.アー. | 強化された摩耗抵抗性を持つ鋳造部品 |
DE60303854T2 (de) | 2003-11-11 | 2006-08-10 | Mattern, Udo | Nasenformulierung mit kontrollierter Freisetzung von Sexualhormonen |
US8784869B2 (en) | 2003-11-11 | 2014-07-22 | Mattern Pharma Ag | Controlled release delivery system for nasal applications and methods of treatment |
PT1750766E (pt) | 2004-05-11 | 2013-09-30 | Emotional Brain Bv | Formulações farmacêuticas e suas utilizações no tratamento de disfunção sexual feminina |
US20060140820A1 (en) | 2004-12-28 | 2006-06-29 | Udo Mattern | Use of a container of an inorganic additive containing plastic material |
EP1790343A1 (en) * | 2005-11-11 | 2007-05-30 | Emotional Brain B.V. | Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction |
GB2437488A (en) * | 2006-04-25 | 2007-10-31 | Optinose As | Pharmaceutical oily formulation for nasal or buccal administration |
EP2068825B1 (en) * | 2006-10-04 | 2011-01-26 | M & P Patent Aktiengesellschaft | Controlled release delivery system for nasal application of neurotransmitters |
US8147980B2 (en) | 2006-11-01 | 2012-04-03 | Aia Engineering, Ltd. | Wear-resistant metal matrix ceramic composite parts and methods of manufacturing thereof |
EP1925307A1 (en) | 2006-11-03 | 2008-05-28 | Emotional Brain B.V. | Use of 3-alpha-androstanediol in the treatment of sexual dysfunction |
DE102010023949A1 (de) * | 2010-06-16 | 2011-12-22 | F. Holzer Gmbh | In-situ Lecithin-Mikroemulsionsgel-Formulierung |
GB2482868A (en) | 2010-08-16 | 2012-02-22 | Franciscus Wilhelmus Henricus Maria Merkus | A testosterone liquid spray formulation for oromucosal administration |
US20130040922A1 (en) * | 2011-05-13 | 2013-02-14 | Trimel Pharmaceuticals Corporation | Intranasal 0.45% and 0.48% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
US20130040923A1 (en) | 2011-05-13 | 2013-02-14 | Trimel Pharmaceuticals Corporation | Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
WO2012156821A1 (en) * | 2011-05-13 | 2012-11-22 | Trimel Pharmaceuticals Corp. | Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
US20130045958A1 (en) * | 2011-05-13 | 2013-02-21 | Trimel Pharmaceuticals Corporation | Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
US9757388B2 (en) | 2011-05-13 | 2017-09-12 | Acerus Pharmaceuticals Srl | Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels |
KR20210135003A (ko) * | 2011-05-15 | 2021-11-11 | 에이세러스 바이오파마 인크. | 비내용 테스토스테론 바이오-접착제 겔 제형 및 남성의 성선기능저하증을 치료하기 위한 그의 용도 |
EA039080B1 (ru) * | 2011-05-16 | 2021-12-01 | Эйсерус Биофарма Инк. | Интраназальные биоадгезивные тестостероновые составы в виде гелей и их применение для лечения мужского гипогонадизма |
EP3936133A1 (en) | 2011-11-23 | 2022-01-12 | TherapeuticsMD, Inc. | Natural combination hormone replacement formulations and therapies |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
JP6262722B2 (ja) | 2012-05-11 | 2018-01-17 | ジェムバックス アンド カエル カンパニー,リミティド | 関節リウマチの予防用または治療用組成物 |
CN115927242A (zh) | 2012-05-11 | 2023-04-07 | 珍白斯凯尔有限公司 | 具有抗炎活性的肽及其在制备抗炎组合物中的应用 |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
CN104822698B (zh) | 2012-07-11 | 2018-08-10 | 珍白斯凯尔有限公司 | 细胞穿透肽以及包含该肽的缀合物和组合物 |
WO2014076569A2 (en) * | 2012-11-14 | 2014-05-22 | Trimel Biopharma Srl | Controlled release topical testosterone formulations and methods |
WO2014083432A2 (en) * | 2012-11-14 | 2014-06-05 | Trimel Biopharma Srl | Female intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11744838B2 (en) | 2013-03-15 | 2023-09-05 | Acerus Biopharma Inc. | Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event |
CN105263508B (zh) | 2013-04-19 | 2019-10-25 | 珍白斯凯尔有限公司 | 治疗和预防缺血性损伤的组合物 |
CN105535931A (zh) | 2013-06-07 | 2016-05-04 | 凯尔杰姆维克斯有限公司 | 在癌症免疫疗法中有用的生物标记 |
ES2808076T3 (es) | 2013-06-21 | 2021-02-25 | Gemvax & Kael Co Ltd | Regulador de la secreción hormonal, composición que lo contiene y procedimiento para controlar la secreción hormonal mediante su uso |
CN105899224B (zh) | 2013-10-23 | 2019-12-13 | 珍白斯凯尔有限公司 | 用于治疗和预防良性前列腺增生的组合物 |
ES2818921T3 (es) | 2013-11-22 | 2021-04-14 | Gemvax & Kael Co Ltd | Péptido que tiene actividad inhibidora de la angiogénesis y composición que contiene el mismo |
EP3085380B1 (en) | 2013-12-17 | 2020-06-17 | Gemvax & Kael Co., Ltd. | Composition for treating prostate cancer |
WO2015156649A1 (ko) | 2014-04-11 | 2015-10-15 | 주식회사 젬백스앤카엘 | 섬유증 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물 |
US10662223B2 (en) | 2014-04-30 | 2020-05-26 | Gemvax & Kael Co., Ltd. | Composition for organ, tissue, or cell transplantation, kit, and transplantation method |
KR20170005819A (ko) | 2014-05-22 | 2017-01-16 | 쎄러퓨틱스엠디, 인코퍼레이티드 | 천연 복합 호르몬 대체 제형 및 요법 |
JP2017523138A (ja) | 2014-07-29 | 2017-08-17 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | 経皮クリーム |
CN106922128B (zh) | 2014-08-28 | 2021-04-02 | 得克萨斯州大学系统董事会 | 睾酮制剂及其治疗方法 |
KR102413243B1 (ko) | 2014-12-23 | 2022-06-27 | 주식회사 젬백스앤카엘 | 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물 |
CN107405380B (zh) | 2015-02-27 | 2021-04-20 | 珍白斯凯尔有限公司 | 用于预防听觉损伤的肽及其包含该肽的组合物 |
WO2017003267A1 (ko) | 2015-07-02 | 2017-01-05 | 주식회사 젬백스앤카엘 | 항바이러스 활성 효능을 가지는 펩티드 및 이를 포함하는 조성물 |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
BR102015020878B1 (pt) * | 2015-08-28 | 2019-08-27 | F B M Ind Farmaceutica Ltda | formulação farmacêutica nasal de testosterona e “kit” em forma de cartela de dispositivos nasais unitários para aplicação de monodose de testosterona. |
CA3016542A1 (en) * | 2016-03-02 | 2017-09-08 | Board Of Regents, The University Of Texas System | Formulations of testosterone and methods of treatment therewith |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
AU2017239645A1 (en) | 2016-04-01 | 2018-10-18 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
JP7114481B2 (ja) | 2016-04-07 | 2022-08-08 | ジェムバックス アンド カエル カンパニー,リミティド | テロメラーゼ活性の増加及びテロメアの延長の効能を有するペプチド、及びこれを含む組成物 |
EA201892595A1 (ru) | 2016-06-03 | 2019-06-28 | М Эт П Фарма Аг | Назальные фармацевтические композиции с пористым наполнителем |
RU2019123307A (ru) | 2017-01-20 | 2021-02-20 | М Эт П Фарма Аг | Фармацевтические композиции для назального введения для снижения рисков воздействия загрязнителей воздуха |
ES2807798T3 (es) | 2017-02-02 | 2021-02-24 | Otolanum Ag | Composición intranasal que comprende betahistina |
EP3718550A4 (en) * | 2017-11-27 | 2021-08-25 | ASKA Pharmaceutical Co., Ltd. | POWDER PREPARATION FOR NASAL ADMINISTRATION |
CN111902188A (zh) | 2018-01-11 | 2020-11-06 | 马特恩制药股份公司 | 脱髓鞘疾病的治疗 |
EP3773497B1 (en) | 2018-04-09 | 2023-10-18 | Elgan Pharma Ltd. | Oxytocin compositions and methods of use |
US20220062165A1 (en) | 2018-04-17 | 2022-03-03 | M et P Pharma AG | Compositions and methods for intranasal delivery of pregnenolone |
AU2019365255A1 (en) * | 2018-10-26 | 2021-06-03 | Viramal Limited | Mucoadhesive gel composition |
CA3123301A1 (en) * | 2018-12-14 | 2020-06-18 | Acerus Biopharma Inc. | Nasal pharmaceutical testosterone ester gel compositions for nasal administration and method |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE943792C (de) * | 1949-02-18 | 1956-06-01 | Organon Nv | Verfahren zur Herstellung von injizierbaren Hormonpraeparaten |
GB1032874A (en) | 1964-02-13 | 1966-06-15 | Du Pont | Stabilized polyoxymethylenes |
NL7506407A (nl) * | 1975-05-30 | 1976-12-02 | Akzo Nv | Werkwijze ter bereiding van een oraal werkzaam far- maceutisch preparaat. |
NL7510104A (nl) * | 1975-08-27 | 1977-03-01 | Akzo Nv | Werkwijze ter bereiding van een oraal werkzaam farmaceutisch preparaat. |
DE2548413A1 (de) * | 1975-10-27 | 1977-04-28 | Schering Ag | Depotpraeparate in oeliger ungesaettigter loesung zur intramuskulaeren injektion |
US4315925A (en) * | 1980-05-30 | 1982-02-16 | University Of Kentucky Research Foundation | Method of administering natural female sex hormones |
US4581225A (en) * | 1984-04-25 | 1986-04-08 | Eli Lilly And Company | Sustained release intranasal formulation and method of use thereof |
US4752425A (en) * | 1986-09-18 | 1988-06-21 | Liposome Technology, Inc. | High-encapsulation liposome processing method |
US5049387A (en) * | 1987-03-09 | 1991-09-17 | Alza Corporation | Inducing skin tolerance to a sensitizing drug |
US5690954A (en) * | 1987-05-22 | 1997-11-25 | Danbiosyst Uk Limited | Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material |
JP2543708B2 (ja) * | 1987-07-13 | 1996-10-16 | 旭化成工業株式会社 | 難溶性薬物を封入したエマルジョン製剤の製造方法 |
NL8801670A (nl) * | 1988-07-01 | 1990-02-01 | Walter Adrianus Josephus Johan | Farmaceutisch preparaat. |
GB2237510B (en) | 1989-11-04 | 1993-09-15 | Danbiosyst Uk | Small particle drug compositions for nasal administration |
US5397771A (en) * | 1990-05-10 | 1995-03-14 | Bechgaard International Research And Development A/S | Pharmaceutical preparation |
US5221698A (en) | 1991-06-27 | 1993-06-22 | The Regents Of The University Of Michigan | Bioactive composition |
US5756071A (en) * | 1992-06-03 | 1998-05-26 | Arrowdean Limited | Method for nasally administering aerosols of therapeutic agents to enhance penetration of the blood brain barrier |
SE9301171D0 (sv) * | 1993-04-07 | 1993-04-07 | Ab Astra | Pharmaceutical composition containing lipophilic drugs |
ATE201980T1 (de) | 1994-02-04 | 2001-06-15 | Scotia Lipidteknik Ab | Präparate mit lipophilen trägerstoffen |
GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
US5635203A (en) | 1994-09-29 | 1997-06-03 | Alza Corporation | Transdermal device having decreased delamination |
US5747058A (en) | 1995-06-07 | 1998-05-05 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system |
GB9608719D0 (en) | 1996-04-26 | 1996-07-03 | Scherer Ltd R P | Pharmaceutical compositions |
GB9707934D0 (en) | 1997-04-18 | 1997-06-04 | Danbiosyst Uk | Improved delivery of drugs to mucosal surfaces |
US6624200B2 (en) | 1998-08-25 | 2003-09-23 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
US5877216A (en) * | 1997-10-28 | 1999-03-02 | Vivus, Incorporated | Treatment of female sexual dysfunction |
US5897894A (en) * | 1997-12-29 | 1999-04-27 | General Mills, Inc. | Microwave popcorn with coarse salt crystals and method of preparation |
GB9823246D0 (en) * | 1998-10-24 | 1998-12-16 | Danbiosyst Uk | A nasal drug delivery composition |
GB9828861D0 (en) | 1998-12-31 | 1999-02-17 | Danbiosyst Uk | Compositions |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6761903B2 (en) | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
NZ514290A (en) * | 1999-04-01 | 2003-08-29 | Akzo Nobel Nv | Formulation comprising testosterone undecanoate and castor oil |
US6287588B1 (en) | 1999-04-29 | 2001-09-11 | Macromed, Inc. | Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof |
CO5180583A1 (es) | 1999-06-11 | 2002-07-30 | Watson Pharmaceuticals Inc | Administracion de esteroides androgenicos no orales a las mujeres |
US6309663B1 (en) | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
US20030236236A1 (en) | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
CA2383233C (en) * | 1999-09-21 | 2010-06-08 | Rtp Pharma Inc. | Surface modified particulate compositions of biologically active substances |
US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
AU1261501A (en) | 1999-12-06 | 2001-06-18 | Stanley L. Gore | Compositions and methods for intranasal delivery of active agents to the brain |
US8980290B2 (en) | 2000-08-03 | 2015-03-17 | Antares Pharma Ipl Ag | Transdermal compositions for anticholinergic agents |
US7198801B2 (en) | 2000-08-03 | 2007-04-03 | Antares Pharma Ipl Ag | Formulations for transdermal or transmucosal application |
US20040092494A9 (en) | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
US20030139384A1 (en) | 2000-08-30 | 2003-07-24 | Dudley Robert E. | Method for treating erectile dysfunction and increasing libido in men |
US20020072509A1 (en) | 2000-10-11 | 2002-06-13 | Stein Donald Gerald | Methods for the treatment of a traumatic central nervous system injury |
US6730330B2 (en) * | 2001-02-14 | 2004-05-04 | Gw Pharma Limited | Pharmaceutical formulations |
WO2002069906A2 (en) * | 2001-03-06 | 2002-09-12 | Cellegy Pharmaceuticals, Inc. | Compounds and methods for the treatment of urogenital disorders |
US6833478B2 (en) | 2001-07-13 | 2004-12-21 | Sri International | N,N-dinitramide salts as solubilizing agents for biologically active agents |
JP2005523262A (ja) * | 2002-02-01 | 2005-08-04 | ファイザー・プロダクツ・インク | 薬物及び親油性ミクロ相形成物質の非晶質分散物の医薬組成物 |
IL163981A0 (en) | 2002-03-15 | 2005-12-18 | Unimed Pharmaceuticals Inc | Androgen pharmaceutical composition and method fortreating depression |
US6855332B2 (en) * | 2002-07-03 | 2005-02-15 | Lyfjathroun Hf. | Absorption promoting agent |
US7029657B2 (en) | 2002-08-02 | 2006-04-18 | Balance Pharmaceuticals, Inc. | Nasal spray steroid formulation and method |
US6958142B2 (en) | 2002-08-02 | 2005-10-25 | Balance Pharmaceuticals, Inc. | Nasal spray formulation and method |
US20040259852A1 (en) | 2003-06-18 | 2004-12-23 | White Hillary D. | Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome |
US8784869B2 (en) | 2003-11-11 | 2014-07-22 | Mattern Pharma Ag | Controlled release delivery system for nasal applications and methods of treatment |
DE60303854T2 (de) | 2003-11-11 | 2006-08-10 | Mattern, Udo | Nasenformulierung mit kontrollierter Freisetzung von Sexualhormonen |
WO2005065185A2 (en) | 2003-12-24 | 2005-07-21 | Collegium Pharmaceuticals, Inc. | Temperature-stable formulations, and methods of development thereof |
US20060140820A1 (en) | 2004-12-28 | 2006-06-29 | Udo Mattern | Use of a container of an inorganic additive containing plastic material |
EP2068825B1 (en) | 2006-10-04 | 2011-01-26 | M & P Patent Aktiengesellschaft | Controlled release delivery system for nasal application of neurotransmitters |
-
2003
- 2003-11-11 DE DE60303854T patent/DE60303854T2/de not_active Expired - Lifetime
- 2003-11-11 EP EP03025769A patent/EP1530965B1/en not_active Expired - Lifetime
- 2003-11-11 ES ES03025769T patent/ES2258694T3/es not_active Expired - Lifetime
- 2003-11-11 DK DK03025769T patent/DK1530965T3/da active
- 2003-11-11 AT AT03025769T patent/ATE319426T1/de active
- 2003-11-11 SI SI200330194T patent/SI1530965T1/sl unknown
- 2003-11-11 PT PT03025769T patent/PT1530965E/pt unknown
-
2004
- 2004-02-04 US US10/772,964 patent/US20050100564A1/en not_active Abandoned
- 2004-09-23 MY MYPI20043889A patent/MY131483A/en unknown
- 2004-10-04 TW TW093129982A patent/TWI350176B/zh not_active IP Right Cessation
- 2004-10-05 AR ARP040103611A patent/AR047722A1/es not_active Application Discontinuation
- 2004-10-27 ZA ZA200603115A patent/ZA200603115B/en unknown
- 2004-10-27 CA CA002541498A patent/CA2541498C/en active Active
- 2004-10-27 PL PL379867A patent/PL219338B1/pl unknown
- 2004-10-27 JP JP2006538697A patent/JP4616270B2/ja not_active Expired - Fee Related
- 2004-10-27 WO PCT/EP2004/012122 patent/WO2005044273A1/en not_active Application Discontinuation
- 2004-10-27 RU RU2006120468/15A patent/RU2331423C2/ru active
- 2004-10-27 BR BRPI0416370A patent/BRPI0416370B8/pt not_active IP Right Cessation
- 2004-10-27 AU AU2004286781A patent/AU2004286781B2/en not_active Ceased
- 2004-10-27 KR KR1020067009182A patent/KR100861443B1/ko active IP Right Grant
- 2004-11-02 SA SA04250363A patent/SA04250363B1/ar unknown
-
2006
- 2006-04-18 HR HRP20060147AA patent/HRP20060147B1/hr not_active IP Right Cessation
- 2006-06-07 NO NO20062619A patent/NO338665B1/no not_active IP Right Cessation
- 2006-11-15 US US11/560,187 patent/US20070149454A1/en not_active Abandoned
-
2010
- 2010-06-08 US US12/796,165 patent/US20100311707A1/en not_active Abandoned
-
2011
- 2011-07-29 US US13/194,853 patent/US8784882B2/en not_active Expired - Lifetime
- 2011-07-30 US US13/194,928 patent/US8574622B2/en not_active Expired - Lifetime
- 2011-12-10 US US13/316,494 patent/US8877230B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20062619L (no) | Doseringssystem med kontrollert frigivning for nasale anvendelser | |
NO20062504L (no) | Sammensetninger og doseringsformer for forbedret absorpsjon | |
NO20061925L (no) | Farmasoytiske preparater for forebyggelse av overdose eller misbruk | |
TW200633716A (en) | Compositions and methods for stabilizing active pharmaceutical ingredients | |
WO2006124047A3 (en) | Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent | |
NO20063411L (no) | Fremgangsmater og doseringsformer for okt opploselighet av legemiddelbestanddeler for kontrollert frigiving | |
EA200800360A1 (ru) | Формуляции с высоким содержанием лекарства и дозированные формы | |
MY151468A (en) | Controlled release solid preparation | |
WO2007016388A3 (en) | Liquid formulations for controlled delivery of benzisoxazole derivatives | |
CY1113462T1 (el) | Μορφη δοσολογιας περιεχουσα παντοπραζολη ως δραστικο συστατικο | |
MXPA06011467A (es) | Combinacion de sustancias activas que comprenden un carbinol combinado con al menos un farmaco antiinflamatorio no esteroideo (nsaid). | |
NO20060445L (no) | Fast farmasoytisk preparat omfattende amisulprid | |
NO20064934L (no) | Fremgangsmate for fremstilling av et fast, farmasoytisk preparat | |
IS8430A (is) | Lyf sem inniheldur (2R)-2-própýloktansýru sem virka efnisþáttinn | |
ECSP034826A (es) | Método para fabricar una composición farmacéutica de dosis baja | |
ATE262893T1 (de) | Darreichungsformen zur behandlung von oralen mykosen | |
DK1359939T3 (da) | Sammensætning og fremgangsmåde til potensering af lægemidler | |
WO2007009691A3 (en) | Combination of substituted pyrazolines and anti -addictive agent | |
WO2003020214A3 (en) | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs | |
ATE460934T1 (de) | Pharmazeutische zubereitungen von ciprofloxacin | |
TR200301553A1 (tr) | İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar | |
DK1273301T3 (da) | Farmaceutiske præparater baseret på aktive bestanddele der kan anvendes til ulovlig administration | |
DE602004022515D1 (de) | Fenofibrate tablett und verfahren zur herstellung | |
EA200601015A1 (ru) | Пероральные композиции дезоксипеганина и их применение | |
SE0203817D0 (sv) | New composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |